Why Intra-Cellular Therapies Stock Is Skyrocketing Today
Shares of Intra-Cellular Therapies (NASDAQ: ITCI) were skyrocketing 80.3% higher as of 11:41 a.m. EDT on Wednesday. The huge jump came after the company announced positive results from a late-stage study evaluating lumateperone as adjunctive therapy to lithium or valproate in treating major depressive episodes associated with bipolar I or bipolar II disorder.
Intra-Cellular Therapies has already picked up an FDA approval for lumateperone in treating schizophrenia. Its latest clinical results could mean that a second approved indication is on the way.
Image source: Getty Images.
Source Fool.com
